Qihui Liu
Research Subjects
Qihui Liu has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Fangfang Chen
State Key Laboratory of Inorganic Synthesis and Preparative Chemistry Key Laboratory of Pathobiology Ministry of Education Nanomedicine and Translational Research Center China‐Japan Union Hospital of Jilin University Changchun China
6 shared publications Yuanyuan Li
Key Laboratory of Pathobiology, Ministry of Education, Nanomedicine and Translational Research Center
4 shared publicationsWenwen Su
Key Laboratory of Pathobiology, Ministry of Education, Nanomedicine and Translational Research Center
3 shared publicationsYangyang Zhao
Key Laboratory of Pathobiology, Ministry of Education, Nanomedicine and Translational Research Center
3 shared publicationsBin Tian
Key Laboratory of Pathobiology, Ministry of Education, Nanomedicine and Translational Research Center
2 shared publicationsGuang Yang
Department of Internal Medicine I, Huguang Campus
2 shared publications
Latest Publications
- 5 May 2026
- Published by American Chemical Society (ACS) in Nano Letters
- Vol. 26 (19) , 6419-6430
Protein Corona-Tailored Nanoplatform Boosts Tumor Accumulation and Reprograms Macrophages for Osteosarcoma Therapy
Osteosarcoma is featured with an immunosuppressive tumor microenvironment (TME) and limited therapeutic efficacy. Herein, we report a pH-responsive nanoplatform based on calcium phosphate (CaP)-coated Prussian blue nanoparticles (PB@CaP NPs) for optimized systemic delivery and antitumor immune response. The CaP interface inhibits the protein corona formation in blood, reducing complement-mediated clearance and prolonging circulation, and enhancing tumor accumulation of the nanoparticles. The pH-responsive dissolution of PB@CaP NPs enables the sequential release of calcium ions in the acidic TME and iron ions in lysosomes, together with the peroxidase-like catalytic activity of the PB core, establishing a synergistic ion/nanozyme signaling axis that triggers robust ROS generation and oxidative stress, thereby reprogramming tumor-associated macrophages from an immunosuppressive M2-like to a pro-inflammatory M1-like phenotype and remodeling the tumor immune microenvironment. This study provides a rational surface engineering strategy for nanoimmunotherapy.
- 5 May 2026
- Published by American Chemical Society (ACS) in Nano Letters
- Vol. 26 (19) , 6419-6430
Protein Corona-Tailored Nanoplatform Boosts Tumor Accumulation and Reprograms Macrophages for Osteosarcoma Therapy
Osteosarcoma is featured with an immunosuppressive tumor microenvironment (TME) and limited therapeutic efficacy. Herein, we report a pH-responsive nanoplatform based on calcium phosphate (CaP)-coated Prussian blue nanoparticles (PB@CaP NPs) for optimized systemic delivery and antitumor immune response. The CaP interface inhibits the protein corona formation in blood, reducing complement-mediated clearance and prolonging circulation, and enhancing tumor accumulation of the nanoparticles. The pH-responsive dissolution of PB@CaP NPs enables the sequential release of calcium ions in the acidic TME and iron ions in lysosomes, together with the peroxidase-like catalytic activity of the PB core, establishing a synergistic ion/nanozyme signaling axis that triggers robust ROS generation and oxidative stress, thereby reprogramming tumor-associated macrophages from an immunosuppressive M2-like to a pro-inflammatory M1-like phenotype and remodeling the tumor immune microenvironment. This study provides a rational surface engineering strategy for nanoimmunotherapy.
- Open Access
- 24 February 2026
- Published by Elsevier in Materials Today Bio
- Vol. 37, 102968
Precise regulation of cancer vaccine and immune checkpoint inhibitor synergy potentiates immunotherapy with reduced immune-related pneumonitis
- 24 February 2026
- Published by Elsevier in Materials Today Bio
- Vol. 37, 102968
Open AccessPrecise regulation of cancer vaccine and immune checkpoint inhibitor synergy potentiates immunotherapy with reduced immune-related pneumonitis
- Open Access
- 1 October 2025
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 20, 12913-12937
Nanotechnology-Driven Strategies in Osteosarcoma Advances in Treatment: Immunotherapy and Drug Delivery
Osteosarcoma (OS), the most prevalent primary malignant bone tumor, exhibits highly aggressive and metastatic potential, accounting approximately 56% of all primary malignant bone malignancies. While neoadjuvant chemotherapy with surgery remains standard, challenges persist: suboptimal margins, non-specific drug biodistribution, and systemic toxicity. Nanomaterial engineering offers transformative multifunctional platforms, integrating biomimetic targeting, stimuli-responsive release, and theranostics to enhance tumor penetration and reduce off-target effects. Immunotherapy combats OS by activating antitumor immunity, reprogramming the immunosuppressive tumor microenvironment (TME), and synergizing with checkpoint inhibitors/cell therapies. Ligand-functionalized nanocarriers significantly improve chemotherapeutic bioavailability and targeting. This review systematically explores the dual role of nanoplatforms in osteosarcoma therapeutics: (1) immunotherapy via TME reprogramming and (2) precision oncology through advanced drug delivery paradigms, providing critical insights into their translational potential for overcoming current therapeutic bottlenecks and ultimately improving clinical outcomes for OS patients.
- 1 October 2025
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 20, 12913-12937
Open AccessNanotechnology-Driven Strategies in Osteosarcoma Advances in Treatment: Immunotherapy and Drug Delivery
Osteosarcoma (OS), the most prevalent primary malignant bone tumor, exhibits highly aggressive and metastatic potential, accounting approximately 56% of all primary malignant bone malignancies. While neoadjuvant chemotherapy with surgery remains standard, challenges persist: suboptimal margins, non-specific drug biodistribution, and systemic toxicity. Nanomaterial engineering offers transformative multifunctional platforms, integrating biomimetic targeting, stimuli-responsive release, and theranostics to enhance tumor penetration and reduce off-target effects. Immunotherapy combats OS by activating antitumor immunity, reprogramming the immunosuppressive tumor microenvironment (TME), and synergizing with checkpoint inhibitors/cell therapies. Ligand-functionalized nanocarriers significantly improve chemotherapeutic bioavailability and targeting. This review systematically explores the dual role of nanoplatforms in osteosarcoma therapeutics: (1) immunotherapy via TME reprogramming and (2) precision oncology through advanced drug delivery paradigms, providing critical insights into their translational potential for overcoming current therapeutic bottlenecks and ultimately improving clinical outcomes for OS patients.
- Open Access
- 21 March 2025
- Published by Wiley in Interdisciplinary Medicine
- Vol. 3 (3)
Nanomaterials for acute myeloid leukemia therapy: Current progress and future perspectives
Acute myeloid leukemia (AML) is a highly aggressive hematologic malignancy characterized by poor prognosis, high relapse rates, and resistance to conventional chemotherapy. The limitations of standard treatments, including systemic toxicity and non‐specific drug distribution, highlight the need for novel therapeutic strategies. Nanoparticles (NPs) represent a promising approach for enhancing AML treatment by improving drug solubility, bioavailability, and targeted delivery while simultaneously minimizing adverse effects. Various NPs, including liposomes, polymeric micelles, dendrimers, carbon‐based, and metal NPs, have been explored for their ability to selectively target leukemic cells through passive and active targeting mechanisms. Functionalized NPs can exploit the enhanced permeability and retention effect for passive accumulation in leukemia‐affected tissues, while ligand‐modified NPs enable active targeting of AML‐specific biomarkers such as CD33, CD123, and folate receptors. Furthermore, NPs facilitate combination therapies, controlled drug release, and intracellular drug delivery, overcoming multidrug resistance and enhancing therapeutic efficacy. This review discusses the latest advancements in NP‐based AML therapies, their targeting strategies, and prospects for clinical translation, emphasizing the potential of nanotechnology in revolutionizing AML treatment.
- 21 March 2025
- Published by Wiley in Interdisciplinary Medicine
- Vol. 3 (3)
Open AccessNanomaterials for acute myeloid leukemia therapy: Current progress and future perspectives
Acute myeloid leukemia (AML) is a highly aggressive hematologic malignancy characterized by poor prognosis, high relapse rates, and resistance to conventional chemotherapy. The limitations of standard treatments, including systemic toxicity and non‐specific drug distribution, highlight the need for novel therapeutic strategies. Nanoparticles (NPs) represent a promising approach for enhancing AML treatment by improving drug solubility, bioavailability, and targeted delivery while simultaneously minimizing adverse effects. Various NPs, including liposomes, polymeric micelles, dendrimers, carbon‐based, and metal NPs, have been explored for their ability to selectively target leukemic cells through passive and active targeting mechanisms. Functionalized NPs can exploit the enhanced permeability and retention effect for passive accumulation in leukemia‐affected tissues, while ligand‐modified NPs enable active targeting of AML‐specific biomarkers such as CD33, CD123, and folate receptors. Furthermore, NPs facilitate combination therapies, controlled drug release, and intracellular drug delivery, overcoming multidrug resistance and enhancing therapeutic efficacy. This review discusses the latest advancements in NP‐based AML therapies, their targeting strategies, and prospects for clinical translation, emphasizing the potential of nanotechnology in revolutionizing AML treatment.
- Open Access
- 7 February 2025
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 184, 117897
Exploring the immuno-nano nexus: A paradigm shift in tumor vaccines
- 7 February 2025
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 184, 117897
Open AccessExploring the immuno-nano nexus: A paradigm shift in tumor vaccines
- 18 December 2024
- Published by American Chemical Society (ACS) in Nano Letters
- Vol. 25 (1) , 147-156
Dual-Targeted Drug Delivery to Myeloid Leukemia Cells via Complement- and Transferrin-Based Protein Corona
Although traditionally regarded as an impediment, the protein corona can facilitate the advancement of targeted drug delivery systems. This study presents an innovative approach for targeting acute myeloid leukemia (AML) using nanoparticles with agglutinated protein (NAPs). Agglutinated transferrin and C3b in NAPs selectively bind to CD71 and CD11b, receptors that are overexpressed on myeloid leukemic cells compared to nonmalignant cells. In vitro, NAPs achieved a 73.9% doxorubicin (DOX) uptake in leukemic cells, compared to 6.19% for the free drug, while significantly reducing off-target accumulation in normal cells from 42.9% to 5.76%. In vivo, the distribution of NAPs correlated to the organ infiltration pattern of leukemic cells. NAPs demonstrated antileukemic activity in both in vitro and in vivo NSG mouse models, inducing cell death via apoptosis and ferroptosis. In conclusion, NAP-mediated targeted drug delivery represents a promising therapeutic strategy for AML, enhancing treatment efficacy and minimizing off-target effects.
- 18 December 2024
- Published by American Chemical Society (ACS) in Nano Letters
- Vol. 25 (1) , 147-156
Dual-Targeted Drug Delivery to Myeloid Leukemia Cells via Complement- and Transferrin-Based Protein Corona
Although traditionally regarded as an impediment, the protein corona can facilitate the advancement of targeted drug delivery systems. This study presents an innovative approach for targeting acute myeloid leukemia (AML) using nanoparticles with agglutinated protein (NAPs). Agglutinated transferrin and C3b in NAPs selectively bind to CD71 and CD11b, receptors that are overexpressed on myeloid leukemic cells compared to nonmalignant cells. In vitro, NAPs achieved a 73.9% doxorubicin (DOX) uptake in leukemic cells, compared to 6.19% for the free drug, while significantly reducing off-target accumulation in normal cells from 42.9% to 5.76%. In vivo, the distribution of NAPs correlated to the organ infiltration pattern of leukemic cells. NAPs demonstrated antileukemic activity in both in vitro and in vivo NSG mouse models, inducing cell death via apoptosis and ferroptosis. In conclusion, NAP-mediated targeted drug delivery represents a promising therapeutic strategy for AML, enhancing treatment efficacy and minimizing off-target effects.
- Open Access
- 29 November 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-16
Specific surface-modified iron oxide nanoparticles trigger complement-dependent innate and adaptive antileukaemia immunity
Considerable advances have been achieved in the application of nanomaterials for immunotherapies, yet the precise immune effects induced by protein corona remain elusive. Here, we explore the formation mechanism and immune regulation process of protein corona in acute myeloid leukaemia (AML) mouse models using commercialized iron oxide nanoparticles (IONPs), with different surface modifications, including an FDA-approved variant. Using macrophages depleted or Complement Component 3 (C3) knockout mice, we demonstrate that carboxymethyl dextran-coated IONP (IONP-COOH) reduces leukaemia burden. Mechanistically, IONP-COOH indirectly binds to C3b after activating the complement alternative pathway, subsequently enhancing phagocytosis of macrophages and activating adaptive immunity mediated by complement corona. While aminated dextran-coated IONPs directly absorb C3b and activate the lectin pathway, leading to immune cell exhaustion. Our findings suggest that IONP-COOH may serve as an immune activator for AML treatment, offering a promising approach to developing therapeutic nanomaterials by leveraging surface chemistry to enhance immunotherapy.
- 29 November 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-16
Open AccessSpecific surface-modified iron oxide nanoparticles trigger complement-dependent innate and adaptive antileukaemia immunity
Considerable advances have been achieved in the application of nanomaterials for immunotherapies, yet the precise immune effects induced by protein corona remain elusive. Here, we explore the formation mechanism and immune regulation process of protein corona in acute myeloid leukaemia (AML) mouse models using commercialized iron oxide nanoparticles (IONPs), with different surface modifications, including an FDA-approved variant. Using macrophages depleted or Complement Component 3 (C3) knockout mice, we demonstrate that carboxymethyl dextran-coated IONP (IONP-COOH) reduces leukaemia burden. Mechanistically, IONP-COOH indirectly binds to C3b after activating the complement alternative pathway, subsequently enhancing phagocytosis of macrophages and activating adaptive immunity mediated by complement corona. While aminated dextran-coated IONPs directly absorb C3b and activate the lectin pathway, leading to immune cell exhaustion. Our findings suggest that IONP-COOH may serve as an immune activator for AML treatment, offering a promising approach to developing therapeutic nanomaterials by leveraging surface chemistry to enhance immunotherapy.
- Open Access
- 3 May 2024
- Published by Elsevier in Acta Biomaterialia
- Vol. 181, 391-401
A biomimetic ion channel shortens the QT interval of type 2 long QT syndrome through efficient transmembrane transport of potassium ions
- 3 May 2024
- Published by Elsevier in Acta Biomaterialia
- Vol. 181, 391-401
Open AccessA biomimetic ion channel shortens the QT interval of type 2 long QT syndrome through efficient transmembrane transport of potassium ions
- 25 April 2017
- Published by Georg Thieme Verlag KG in Seminars in Thrombosis and Hemostasis
- Vol. 43 (06) , 629-634
Clinical Significance of Antinuclear and Antiextractable Nuclear Antigen Antibody in Childhood Immune Thrombocytopenia
This study aims to determine the clinical significance of positive antinuclear/antiextractable nuclear antigen (ANA/A-ENA) antibody on manifestation and therapeutic response of childhood immune thrombocytopenia (ITP). Overall, 1,330 patients aged between 1 and 15.6 years diagnosed with primary ITP were retrospectively analyzed, excluding those with secondary ITP. Bleeding manifestations were recorded. All patients underwent autoantibody testing and follow-up for 32 months on average (range: 23–54 months). Steroid response was also assessed. Response rates were compared between ANA/A-ENA–positive and ANA/A-ENA–negative patients. Of all the patients enrolled, 84 tested positive only for ANA, 102 tested positive for A-ENA, 54 tested positive for both ANA and A-ENA, and 1,090 tested negative for both. Patients who were ANA/A-ENA positive were more likely to be female and older than 10 years. Patients who were A-ENA positive were more likely to have either persistent or chronic disease and suffer from life-threatening bleeding as well as poor short-term therapeutic response. We conclude that autoantibody testing is important to determine the short-term prognosis of ITP patients. Females, patients older than 10 years of age, and patients with either mixed positivity or A-ENA positivity should be more closely monitored.
- 25 April 2017
- Published by Georg Thieme Verlag KG in Seminars in Thrombosis and Hemostasis
- Vol. 43 (06) , 629-634
Clinical Significance of Antinuclear and Antiextractable Nuclear Antigen Antibody in Childhood Immune Thrombocytopenia
This study aims to determine the clinical significance of positive antinuclear/antiextractable nuclear antigen (ANA/A-ENA) antibody on manifestation and therapeutic response of childhood immune thrombocytopenia (ITP). Overall, 1,330 patients aged between 1 and 15.6 years diagnosed with primary ITP were retrospectively analyzed, excluding those with secondary ITP. Bleeding manifestations were recorded. All patients underwent autoantibody testing and follow-up for 32 months on average (range: 23–54 months). Steroid response was also assessed. Response rates were compared between ANA/A-ENA–positive and ANA/A-ENA–negative patients. Of all the patients enrolled, 84 tested positive only for ANA, 102 tested positive for A-ENA, 54 tested positive for both ANA and A-ENA, and 1,090 tested negative for both. Patients who were ANA/A-ENA positive were more likely to be female and older than 10 years. Patients who were A-ENA positive were more likely to have either persistent or chronic disease and suffer from life-threatening bleeding as well as poor short-term therapeutic response. We conclude that autoantibody testing is important to determine the short-term prognosis of ITP patients. Females, patients older than 10 years of age, and patients with either mixed positivity or A-ENA positivity should be more closely monitored.
- 1 October 2013
- Published by SAGE Publications in Journal of Investigative Medicine
- Vol. 61 (7) , 1121-1128
Racial Disparities in Hepatitis B Infection in Ohio
Objective Chronic hepatitis B virus (HBV) infection and liver cancer mortality represent a neglected health disparity among Asian Americans. The purposes of this study were to compare the prevalence of hepatitis B among a diverse group of 1311 Ohioans in Franklin County, OH (85% Asians, 7.5% African Americans, and 6.5% whites) and to improve access to care for high-risk Asian adults through advocacy and policy changes. Research Design and Methods The Asian subgroups comprised of Chinese, Filipino, Asian Indian, Pakistani, Vietnamese, Korean, Laotian, Indonesian, Japanese, Cambodian, Thai, and Malaysian nationalities. The HBV screening was completed at health fairs, restaurants, churches, and temples from 2006 to 2011. Results The prevalence of HBV infection (9.5% vs 5%) and family history of liver cancer was significantly higher among Asians than other racial ethnic groups (P = 0.001). Cambodian, Vietnamese, and Chinese participants were disproportionately infected with the virus compared with other Asian subgroups (P < 0.001). Advocacy and policy changes for resources allowed vaccine-eligible Asians included as “high risk” group to receive free vaccinations at the health department. However, although vouchers were provided to vaccine-eligible Asian adults, compliance in getting vaccinated was very low (11%). Common barriers for compliance were lack of time and knowledge of completing the 3 shot series, low English proficiency, and fear of adverse effects. Conclusions Outreach education may use community liaisons to improve screenings, education, and vaccination/treatment. A hepatitis free clinic was established in 2009 to provide culturally and linguistically appropriate treatment for low-income Asian Americans in Franklin County, OH.
- 1 October 2013
- Published by SAGE Publications in Journal of Investigative Medicine
- Vol. 61 (7) , 1121-1128
Racial Disparities in Hepatitis B Infection in Ohio
Objective Chronic hepatitis B virus (HBV) infection and liver cancer mortality represent a neglected health disparity among Asian Americans. The purposes of this study were to compare the prevalence of hepatitis B among a diverse group of 1311 Ohioans in Franklin County, OH (85% Asians, 7.5% African Americans, and 6.5% whites) and to improve access to care for high-risk Asian adults through advocacy and policy changes. Research Design and Methods The Asian subgroups comprised of Chinese, Filipino, Asian Indian, Pakistani, Vietnamese, Korean, Laotian, Indonesian, Japanese, Cambodian, Thai, and Malaysian nationalities. The HBV screening was completed at health fairs, restaurants, churches, and temples from 2006 to 2011. Results The prevalence of HBV infection (9.5% vs 5%) and family history of liver cancer was significantly higher among Asians than other racial ethnic groups (P = 0.001). Cambodian, Vietnamese, and Chinese participants were disproportionately infected with the virus compared with other Asian subgroups (P < 0.001). Advocacy and policy changes for resources allowed vaccine-eligible Asians included as “high risk” group to receive free vaccinations at the health department. However, although vouchers were provided to vaccine-eligible Asian adults, compliance in getting vaccinated was very low (11%). Common barriers for compliance were lack of time and knowledge of completing the 3 shot series, low English proficiency, and fear of adverse effects. Conclusions Outreach education may use community liaisons to improve screenings, education, and vaccination/treatment. A hepatitis free clinic was established in 2009 to provide culturally and linguistically appropriate treatment for low-income Asian Americans in Franklin County, OH.